The Food and Drug Administration (FDA) is considering what it terms “potential regulatory pathways” for the interstate commerce of hemp and cannabis compounds in foods and beverages. This follows the renewal of the Farm Bill signed by President Donald Trump on Dec. 20, which legalized the commercial production of hemp.
The legalization of hemp production is yet another product of the wave of change that has all manner of cannabis companies preparing for the massive increase in demand for the plants including leading providers like Aphria (TSX: APH) (OTCQB: APHQF), Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF), and MedMen (CSE: MMEN) (OTC: MMNFF).
With this news in hand, the CBD products sector is expected to grow significantly. One stand out in this area is The Yield Growth Corp., which holds multiple interests. The Yield …View the full post at: How Does the FDA Plan to Deal with Hemp Now That It’s Legal? …